Bibliography
- Hetherington MM, Cecil JE. Gene-environment interactions in obesity. Forum Nutr 2010;63:195-203
- Compared with whites, Blacks had 51% higher and Hispanics had 21% higher obesity rate. Centers for Disease Control, Atlanta, GA, 2014. Available from: http://www.cdc.gov/Features/dsObesityAdults/
- Gale SM, Castracane VD, Mantzoros CS. Energy homeostasis, obesity and eating disorders: recent advances in endocrinology. J Nutr 2004;134:295-8
- Finkelstein EA, Trogdon JG, Cohen JW, et al. Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Aff 2009;28:w822-31
- Schneider BE, Mun EC. Surgical management of morbid obesity. Diabetes Care 2005;28:475-80
- Suter M, Calmes JM, Paroz A, et al. Results of Roux-en-Y gastric bypass in morbidly obese vs superobese patients: similar body weight loss, correction of comorbidities, and improvement of quality of life. Arch Surg 2009;144:312-18. discussion 18
- Heal DJ, Gosden J, Smith SL. A review of late-stage CNS drug candidates for the treatment of obesity. Int J Obes 2013;37:107-17
- Valentino MA, Lin JE, Waldman SA. Central and peripheral molecular targets for antiobesity pharmacotherapy. Clin Pharmacol Ther 2010;87:652-62
- Ioannides-Demos LL, Proietto J, Tonkin AM, et al. Safety of drug therapies used for weight loss and treatment of obesity. Drug Saf 2006;29:277-302
- Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. J Am Med Assoc 2014;311:74-86
- Jain SS, Ramanand SJ, Ramanand JB, et al. Evaluation of efficacy and safety of orlistat in obese patients. Indian J Endocrinol Metab 2011;15:99-104
- Woloshin S, Schwartz LM. The new weight-loss drugs, lorcaserin and phentermine-topiramate: slim pickings? JAMA Intern Med 2014;174:615-19
- Aronne LJ, Wadden TA, Peterson C, et al. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults. Obesity (Silver Spring) 2013;21:2163-71
- Shin JH, Gadde KM. Clinical utility of phentermine/topiramate (Qsymia) combination for the treatment of obesity. Diabetes Metab Syndr Obes 2013;6:131-9
- Astrup A, Rossner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009;374:1606-16
- Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring) 2013;21:935-43
- Kopelman P, Groot Gde H, Rissanen A, et al. Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical). Obesity (Silver Spring) 2010;18:108-15
- Novo Nordisk reports 8% weight loss in phase 3a obesity trial with liraglutide 3 mg. Novo Nordisk, 2013. Available from: http://www.novonordisk.com/include/asp/exe_news_attachment.asp?sAttachmentGUID=3f254ec7-1b91-4334-bf0d-572d4e6a4c3e
- Witkamp RF. Current and future drug targets in weight management. Pharm Res 2011;28:1792-818
- Erondu N, Wadden T, Gantz I, et al. Effect of NPY5R antagonist MK-0557 on weight regain after very-low-calorie diet-induced weight loss. Obesity (Silver Spring) 2007;15:895-905
- Nathan PJ, O’Neill BV, Napolitano A, et al. Neuropsychiatric adverse effects of centrally acting antiobesity drugs. CNS Neurosci Ther 2011;17:490-505
- Dietrich MO, Horvath TL. Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons. Nat Rev Drug Discov 2012;11:675-91
- King BM. The rise, fall, and resurrection of the ventromedial hypothalamus in the regulation of feeding behavior and body weight. Physiol Behav 2006;87:221-44
- Collins S, Cao W, Daniel KW, et al. Adrenoceptors, uncoupling proteins, and energy expenditure. Exp Biol Med 2001;226:982-90
- Antel J, Gregory PC, Nordheim U. CB1 cannabinoid receptor antagonists for treatment of obesity and prevention of comorbid metabolic disorders. J Med Chem 2006;49:4008-16
- Cota D, Tschop MH, Horvath TL, et al. Cannabinoids, opioids and eating behavior: the molecular face of hedonism? Brain Res Rev 2006;51:85-107
- Volkow ND, Wang G-J, Baler RD. Reward, dopamine and the control of food intake: implications for obesity. Trends Cogn Sci 2011;15:37-46
- Roses AD. Stimulation of cholecystokinin-A receptors With Gl181771X: a failed clinical trial that did not test the pharmacogenetic hypothesis for reduction of food intake. Clin Pharmacol Ther 2009;85:362-5
- Santoro N, del Giudice EM, Grandone A, et al. Y2 receptor gene variants reduce the risk of hypertension in obese children and adolescents. J Hypertens 2008;26:1590-4
- Heymsfield SB, Greenberg AS, Fujioka K, et al. Recombinant leptin for weight loss in obese and lean adults, A randomized, controlled, dose-escalation trial. JAMA 1999;282:1568-75
- Ravussin E, Smith SR, Mitchell JA, et al. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity (Silver Spring) 2009;17:1736-43
- Tam CS, Lecoultre V, Ravussin E. Novel strategy for the use of leptin for obesity therapy. Expert Opin Biol Ther 2011;11:1677-85
- Ahima RS, Prabakaran D, Mantzoros C, et al. Role of leptin in the neuroendocrine response to fasting. Nature 1996;382:250-2
- Rosenbaum M, Murphy EM, Heymsfield SB, et al. Low dose leptin administration reverses effects of sustained weight-reduction on energy expenditure and circulating concentrations of thyroid hormones. J Clin Endocrinol Metab 2002;87:2391-4
- Kim EJ, Shin WH. General pharmacology of CKD-732, a new anticancer agent: effects on central nervous, cardiovascular, and respiratory system. Biol Pharm Bull 2005;28:217-23
- Kim YM, An JJ, Jin Y-J, et al. Assessment of the anti-obesity effects of the TNP-470 analog, CKD-732. J Mol Endocrinol 2007;38:455-65
- Zafgen, Inc., USA. Treating hypothalamic obesity with methionine aminopeptidase 2 (MetAP2) inhibitors. WO2013169857A1; 2013
- Chun E, Han CK, Yoon JH, et al. Novel inhibitors targeted to methionine aminopeptidase 2 (MetAP2) strongly inhibit the growth of cancers in xenografted nude model. Int J Cancer 2005;114:124-30
- Zafgen announces cardiovascular data from phase 1b study of ZGN-433 in obesity at American diabetes association annual meeting. Zafgen, Cambridge, MA; 2011. Available from: http://zafgen.com/zafgen/newsroom/news-details?ID=f678c3b2-5885-6f14-8089-ff0000fc4595
- Hughes TE, Kim DD, Marjason J, et al. Ascending dose-controlled trial of beloranib, a novel obesity treatment for safety, tolerability, and weight loss in obese women. Obesity (Silver Spring) 2013;21:1782-8
- Rossi J, Balthasar N, Olson D, et al. Melanocortin-4 receptors expressed by cholinergic neurons regulate energy balance and glucose homeostasis. Cell Metab 2011;13:195-204
- Greenfield JR, Miller JW, Keogh JM, et al. Modulation of blood pressure by central melanocortinergic pathways. N Engl J Med 2009;360:44-52
- Krishna R, Gumbiner B, Stevens C, et al. Potent and selective agonism of the melanocortin receptor 4 with MK-0493 does not induce weight loss in obese human subjects: energy intake predicts lack of weight loss efficacy. Clin Pharmacol Ther 2009;86:659-66
- A two part trial investigating an anti-obesity drug in overweight/obese male and female healthy volunteers. National Institutes of Health, Washington, DC; 2014. Available from: http://clinicaltrials.gov/ct2/show/NCT01044108?term=NNC+0070-0002-0453&rank=1
- Sohn J-W, Harris LE, Berglund ED, et al. Melanocortin 4 receptors reciprocally regulate sympathetic and parasympathetic preganglionic neurons. Cell 2013;152:612-19
- Kievit P, Halem H, Marks DL, et al. Chronic treatment with a melanocortin-4 receptor agonist causes weight loss, reduces insulin resistance, and improves cardiovascular function in diet-induced obese rhesus macaques. Diabetes 2013;62:490-7
- Phase 2 study to evaluate safety and efficacy of Rm-493 in obese patients. National Institutes of Health, Washington, DC; 2014. Available from: http://clinicaltrials.gov/ct2/show/NCT01749137?term=RM-493&rank=1
- Effects of RM-493 on energy expenditure in obese individuals. National Institutes of Health, Washington, DC; 2014. Available from: http://clinicaltrials.gov/ct2/show/NCT01867437?term=RM-493&rank=2
- Rhythm Pharmaceuticals, Inc., USA. Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers comprising melanocortin-4 receptor agonist peptides. WO2013102047A1; 2013
- Ipsen grants Rhythm exclusive worldwide license for two programs in the field of metabolic disorders. Boston, MA; 2010. Available from: http://www.rhythmtx.com/NEWS/releases/031210.html
- Ipsen Pharma. A sustained-release composition containing peptides as active ingredient. WO2012172433A2; 2012
- Societe de Conseils de Recherches et D’Applications Scientifiques S.A.S., Fr.; Louisiana State University and Agriculture and Mechanical College; Ipsen Pharma. Use of melanocortin receptor agonist peptide compounds to treat insulin resistance. WO2009061411A2; 2009
- A safety and efficacy study of HPP404 on weight loss in overweight or obese subjects. National Institutes of Health, Washington, DC; 2014. Available from: http://clinicaltrials.gov/ct2/show/NCT01540864?term=HPP404&rank=1
- Passani MB, Blandina P, Torrealba F. The histamine H3 receptor and eating behavior. J Pharmacol Exp Ther 2011;336:24-9
- Berlin M, Boyce CW, de Lera Ruiz M. Histamine H3 receptor as a drug discovery target. J Med Chem 2011;54:26-53
- de Lera Ruiz M, Zheng J, Berlin MY, et al. Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity. Bioorg Med Chem Lett 2013;23:6004-9
- Novo Nordisk A/S, Den. Preparation of 3-(1,3-benzodioxol-5-yl)-6-(4-cyclopropylpiperazin-1-yl)pyridazine as a histamine H3 receptor antagonist. WO2007137968A1; 2007
- Kim E, Campbell S, Schueller O, et al. A small-molecule inhibitor of enterocytic microsomal triglyceride transfer protein, SLx-4090: biochemical, pharmacodynamic, pharmacokinetic, and safety profile. J Pharmacol Exp Ther 2011;337:775-85
- Phase 2 study of orlistat and SLx-4090 for the treatment of type 1 hyperlipoproteinemia. National Institutes of Health, Washington, DC; 2014. Available from: http://clinicaltrials.gov/ct2/show/NCT01675154?term=SLx-&rank=1
- Clinical pipeline. Kadmon, 2014. Available from: http://kadmon.com/docs/science_pipeline
- Cuchel M, Rader DJ. Microsomal transfer protein inhibition in humans. Curr Opin Lipidol 2013;24:246-50
- Wren JA, King VL, Campbell SL, et al. Biologic activity of dirlotapide, a novel microsomal triglyceride transfer protein inhibitor, for weight loss in obese dogs. J Vet Pharmacol Ther 2007;30:33-42
- Hata T, Mera Y, Kawai T, et al. JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, ameliorates impaired glucose and lipid metabolism in Zucker diabetic fatty rats. Diabetes Obes Metab 2011;13:629-38
- Fujimori Y, Katsuno K, Nakashima I, et al. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 2008;327:268-76
- Kapur A, O’Connor-Semmes R, Hussey EK, et al. First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus. BMC Pharmacol Toxicol 2013;14:26
- BHV Pharma - Our pipeline. BHV Pharma, 2014. Available from: http://www.bhvpharma.com/pipeline/
- Bays HE, Weinstein R, Law G, et al. Canagliflozin: effects in overweight and obese subjects without diabetes mellitus. Obesity (Silver Spring) 2014;22:1042-9
- Cefalu WT. Paradoxical insights into whole body metabolic adaptations following SGLT2 inhibition. J Clin Invest 2014;124:485-7
- To investigate the safety, tolerability and pharmacodynamics of GSK2890457 in healthy volunteers and subjects with type 2 diabetes. National Institutes of Health, Washington, DC; 2014. Available from: http://clinicaltrials.gov/ct2/show/NCT01725126?term=GSK-2890457&rank=1
- Ornellas T, Chavez B. Naltrexone SR/bupropion SR (Contrave): a new approach to weight loss in obese adults. P T 2011;36:255-62
- Empatic. Orexigen; 2014. Available from: http://www.orexigen.com/product-candidates/empatic.html
- Exenatide in extreme pediatric obesity. National Institutes of Health, Washington, DC; 2014. Available from: http://clinicaltrials.gov/ct2/show/NCT01237197?term=exenatide+and+Minnesota&rank=2
- Topiramate in adolescents with severe obesity. National Institutes of Health, Washington, DC; 2014. Available from: http://clinicaltrials.gov/ct2/show/NCT01859013?term=topiramate+and+minnesota&rank=1
- The therapeutic effects of topiramate and metformin on second generation antipsychotics-induced obesity. National Institutes of Health, Washington, DC; 2014. Available from: http://clinicaltrials.gov/ct2/show/NCT01384279?term=topiramate+and+metformin+and+taiwan&rank=1
- American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists. et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601
- Hypothalamic obesity following craniopharyngioma surgery: a pilot trial of combined metformin and diazoxide therapy. National Institutes of Health, Washington, DC; 2014. Available from: http://clinicaltrials.gov/ct2/show/NCT00892073?term=Craniopharyngioma++toronto&rank=1
- Amlexanox for type 2 diabetes and obesity. National Institutes of Health, Washington, DC; 2014. Available from: http://clinicaltrials.gov/ct2/show/NCT01842282?term=amlexanox&rank=2
- Reilly SM, Chiang SH, Decker SJ, et al. An inhibitor of the protein kinases TBK1 and IKK-varepsilon improves obesity-related metabolic dysfunctions in mice. Nat Med 2013;19:313-21